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Taguchi et al. describe, in this issue ofCancer Cell, a quantitative comparative biomarker discovery approach
that integrates animal lung cancer models with validation in well-controlled human clinical study sets. This
approach overcomes many of the major barriers that have held back the field of cancer biomarkers in the
past.While opinion leaders are exceedingly
hopeful that ‘‘the ability of biomarkers to
improve treatment and reduce health-
care costs is potentially greater than in
any other area of current medical
research,’’ they have been very pessimistic
that ‘‘research into biomarkers has not yet
delivered on its promise’’ (Poste, 2011).
Poste (2011) recently stated ‘‘Technologies
such as proteomics and DNA microarrays
have contributed a voluminous literature
of more than 150,000 papers documenting
thousands of claimed biomarkers, but
fewer than 100 have been validated for
routine clinical practice. This dismal record
reflects the failure of researchers to
embrace a coordinated systems-based
approach.’’. Taguchi et al. (2011) now
provide fresh optimism that cancer
biomarkers are closer to delivering on their
promise. This is a landmark paper because
it uses a system-based approach to
discover candidate biologically relevant
biomarkers from animal models and tumor
cell lines and then goes on to demonstrate
the relevanceof thesecandidatemarkers in
human lung cancer. Biomarker science in
the past has beenusually limited to a corre-
lation between the level of the marker and
the presence of the disease. This study
goes beyond correlation to causality.
More than a decade ago, the biomarker
field was launched with great enthusiasm
because mass spectrometry revealed that
blood contained a rich archive of potential
biomarkers (Aebersold and Mann, 2003;
Anderson and Anderson, 2002; Petricoin
et al, 2006). Since then, the field of
protein-based biomarker discovery has
been hampered by four major interrelated,
overarching barriers (Table 1).
The first barrier has been the inability to
mechanistically tie thepresenceof a candi-date marker to the biology of the tumor,
which made it difficult to have confidence
in the marker or to understand its true clin-
ical utility. Ideally,weshould link themarker
to a functional role in tumorigenesis and
have the capability to study the cell biology
of themarker in experimentalmodels. Only
then can we rationally determine if the
marker is best suited for early detection in
the general population, high-risk screen-
ing, recurrence monitoring, or individual-
ized therapy. The lack of marker biology
tie-in also has a tremendous impact on
downstream aspects of biomarker devel-
opment. Invariably, mass spectrometry-
based hunts lead to the identification of
dozens tohundredsof candidates.Without
a firm biologic basis for ranking, most
investigators are paralyzed by the sheer
numbers in front of them.
The second barrier has been the lack of
validation in well-controlled human clin-
ical study sets, especially those where
serum/plasma was collected in an
asymptomatic group of subjects that
were later found to have the cancer under
study. The inadequacies of past sample
handling methodologies and procedures
have created anxiety in the community,
as realization has set in that many of our
retrospectively collected study sets with
long-term follow up are likely fraught
with hard-wired biases due to inconsis-
tencies in how samples were collected
and stored (Poste, 2011; Service, 2008).
The third barrier has been the fact that
many investigators fail to plan for the in-
tended use of the biomarker, and thus
omit the appropriate control cohorts. An
example is the common use of controls
from healthy individuals. Healthy individ-
uals’ plasma or sera is not a sufficient
control for modern cancer biomarkerCancer Cell 20, Seresearch. The proper controls must
include patients who are sick with non-
cancer illnesses or harbor benign tumors.
Cancer nearly always occurs in the back-
ground of inflammation, and the aggre-
gate of inflammatory disorders are much
more highly prevalent in the test popula-
tion compared to any single cancer type.
Thus, sadly, many cancer markers are
not specific enough to be used in the
clinic or require re-evaluation in popula-
tion cohorts more suited for the intended
use of the candidate marker.
The fourth major barrier is the lability
and extremely low abundance of cancer
biomarkers in the blood. Biomarkers
emanating from an early stage tumor
mass exist at concentrations that are
usually in the picogram per ml range,
which is ten to fifty fold lower than the
sensitivity of current quantitative mass
spectrometry (Service, 2008; Brown and
Palmer, 2009). Consequently, there exists
an ocean of low abundant biomarkers that
is invisible to conventional mass spec-
trometry-based discovery.
Taguchi et al. (2011) describeaworkflow
that directly addresses the first three of the
aforementioned barriers and provide
compelling evidence that a mass spec-
trometry-drivenproteomicdiscovery effort
mayfinally bepayingdividends. Theyover-
came the first roadblock using an impres-
sive combination of experimental models
that link the biomarker with the cancer
biology. The investigators compared the
plasma proteins in four mouse models of
lung cancerwithmousemodels of pancre-
atic, ovarian, prostate, and breast cancer.
Theseriesofmousemodels independently
cover three known aspects of non-small
cell lung cancer (NSCLC) tumorigenesis:
deregulations in EGFR, KRAS, and p53.ptember 13, 2011 ª2011 Elsevier Inc. 279
Table 1. Breaking the Barriers to Biomarker Discovery
Barrier to Cancer Biomarker Progress Emerging Successful Strategies to Break the Barrier
(1) Failure to mechanistically tie a blood biomarker to the tumor itself (a) Discovery of the biomarker across a series of experimental animal
tumor models,
(b) Mechanistically showing a role in tumorigenesis or a change after
therapy,
(c) Validation of the same marker using human samples,
(2) Improper sample handling and tracking; inadequate tissue fixation
and body fluid sample preservation that generates bias, false
positives, and false negatives
(a) Preservation technologies for tissue and body fluid sample
collection.
(b) Uniform protocols for collection of tissues and body fluids.
(c) Molecular measures to verify the preservation of a biological
sample
(3) Lack of independent blinded clinical validationwith proper controls
for specificity and noncancer diseases
Inclusion of independent epidemiologically credentialed and
matched cohorts with inflammatory disease, infectious disease,
and benign tumors.
(4) Low analytical sensitivity of mass spectrometry-based detection
systems that prevent the detection/identification andmeasurement of
low abundance (<ng/nl) biomarkers emanating from early stage
cancer
Nanotechnology-based methods for biomarker capture,
preservation, and exclusion of unwanted high abundance proteins
such as albumin can amplify mass spectrometry sensitivity 1000 fold
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a major driver of NSCLC (Lynch et al.,
2004). Taguchi et al. identified EGFR
pathway biomarkers in the blood of the
mouse NSCLC model and then verified
the potential clinical utility of the EGFR
protein itself in human study sets. The
investigators were able to identify blood-
borne biomarkers related to the EGFR-
signaling network in the murine system
that changed with response to EGFR-tar-
geted therapeutic. Two models of inflam-
mation were also used. This starting point
for discovery took advantage of the fact
that the animal models could be used to
verify that at least some of the potential
biomarkers were derived from the cancer
cells themselves, and not a reactive
product of thehost.Usingpathway-driving
informatics, specific protein expression
changes were identified in the plasma
that correlated with the underpinning
genetic state of the tumor itself. By using
multiple models of different cancer types,
these investigators directly verified the
biomarker tumor type specificity. The
inclusion of inflammatory controls pro-
vided an important level of assurance that
the candidate markers were not just an
indicator of inflammation.
Addressing the second and third major
barriers, the investigators validated the
clinical potential of the biomarker candi-
dates using two very well-controlled
human plasma study sets, including a set
from presymptomatic patients from the
Carotene and Retinol Efficacy Trial
(CARET) cohort study. Because the clin-280 Cancer Cell 20, September 13, 2011 ª20ical validationwas very rigorous, thepaper
represents a milestone achievement in
protein biomarker discovery that tran-
scends the specific candidate markers
uncovered.
Moving forward from theexample set by
Taguchi et al. (2011), the next generation
of biomarker discovery platforms will use
new technologies such as biomarker-har-
vestingnanoparticles (Luchini et al., 2008);
in one step, in solution, they can concen-
trate and preserve even the most low
abundance proteins, amplifying the sensi-
tivity of mass spectrometry 100 fold or
greater. These new nanotechnologies
address the fourth (Table 1) and last signif-
icant impediment to biomarker discovery.
The ultimate clinical utility of biomarkers
described by Taguchi et al. will require
further large-scale validation. The bio-
markers that change following therapy
could be envisioned as potentially useful
for recurrence or treatment monitoring in
NSCLC patients. While the investigators
provide powerful but preliminary evidence
that the specific marker sets appear to
identify future NSCLC in some of the
presymptomatic patients, it is unlikely
that this would be the immediate intended
use of the markers. In order to be used as
a primary screening tool for large popula-
tions, a blood biomarker for NSCLC must
have extremely high sensitivity and speci-
ficity. Work up for suspected NSCLC
involves costly procedures such as spiral
CT and invasive diagnostic procedures
that have associated morbidity and
mortality. Given the relatively low overall11 Elsevier Inc.specificity of spiral-CT screening for lung
cancer (Harders et al., 2011), it is more
likely that blood-based lung cancer
biomarkerswill first be used in conjunction
with imaging to improve the specificity of
detection for both modalities. This is an
important application for biomarkers that
could truly reverse the curve against this
deadly cancer.REFERENCES
Aebersold, R., and Mann, M. (2003). Nature 422,
198–207.
Anderson, N.L., and Anderson, N.G. (2002). Mol.
Cell. Proteomics 1, 845–867.
Brown, P.O., and Palmer, C. (2009). PLoS Med. 6,
e1000114. 10.1371/journal.pmed.1000114.
Harders, S.W., Madsen, H.H., Rasmussen, T.R.,
Hager, H., and Rasmussen, F. (2011). Acta Radiol.
52, 401–409.
Luchini, A., Geho, D.H., Bishop, B., Tran, D., Xia,
C., Dufour, R.L., Jones, C.D., Espina, V., Patanarut,
A., Zhou, W., et al. (2008). Nano Lett. 8, 350–361.
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagava-
tula, S., Okimoto, R.A., Brannigan, B.W., Harris,
P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G.,
et al. (2004). N. Engl. J. Med. 350, 2129–2139.
Petricoin, E.F., Belluco, C., Araujo, R.P., and Liotta,
L.A. (2006). Nat. Rev. Cancer 6, 961–967.
Poste, G. (2011). Nature 469, 156–157.
Service, R.F. (2008). Science 321, 1758–1761.
Taguchi, A., Politi, K., Pitteri, S.J., Lockwood,
W.W., Fac¸a, V.M., Kelly-Spratt, K., Wong, C.-H.,
Zhang, Q., Chin, A., Park, K.-S., et al. (2011).
Cancer Cell 20, this issue, 289–299.
